Online Business

PSUs may soon have time-frame for nomination of ind directors

With the aggressive disinvestment of PSUs being planned for the coming months, the government is likely to introduce a fixed time-frame during which the nomination of independent directors should be completed by state-run companies. - SAIL, ONGC, IOC, NTPC may get Maharatna tag - Heavy industry PSUs have to go in for energy audits - Mines Ministry to take up Hind Copper disinvestment - Maharatna status to top PSUs likely in six months - "Action plan for further disinvestment likely by March" - Govt expecting Rs 24,000 cr from disinvestment "We are looking at shortening the time span of the process (of nominating independent directors)," Secretary in the Department of Public Enterprises Bhaskar Chatterjee told PTI. He further said the current process is taking a long time. It goes through a number of stages and sometimes the ministries do not respond on time and applications are held up for six to seven months at times. As per market regulator Sebi"s guidelines, it is mandatory for a company to fulfil the criteria of independent directors before getting listed on the bourses or hitting the capital market. Under Clause 49 of the Listing Agreement of Sebi, any listed firm must have at least half of its board constituted by independent directors or non-executive directors, if the chairman is an executive. In case the chairman is non-executive, the rules demand that at least one-third of the board should comprise independent directors.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

News of the day
RBI to raise growth forecast for FY10: Gokarn
Buoyed by better-than-expected GDP growth of 7.9 per cent in the second quarter, the Reserve Bank today said it will have to raise the country"s growth outlook for 2009-10 from the current estimates of 6 per cent.
Popular Articles

Aurobindo gets tentative nod for anti-dementia drug
Aurobindo Pharma Limited, a Hyderabad-based manufacturer of generic pharmaceuticals and active pharmaceutical ingredients (APIs), has received tentative approval for donepezil hydrochloride tablets in 5mg and 10mg strengths from the US Food and Drug Administration (US FDA). The product has a market size of over $1.9 billion.

Markets likely to open on a flat note
The markets are likely to open on a flat note amid mixed cues from the global markets.